<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended OCTOBER 31, 1995
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from _______________ to _________________
Commission file number 0-17085
TECHNICLONE INTERNATIONAL CORPORATION
(Exact name of Registrant as specified in its charter)
<TABLE>
<S> <C>
CALIFORNIA 95-3698422
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification Number)
14282 FRANKLIN AVENUE, TUSTIN, CALIFORNIA 92680
(Address of principal executive offices) (Zip Code)
</TABLE>
(714) 838-0500
(Registrant's telephone number, including area code)
NOT APPLICABLE
(Former name, former address and former fiscal year,
if changed, since last report)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports); and (2) has been subject to such
filing requirements for the past 90 days. YES [X]. NO [ ].
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS
DURING THE PRECEDING FIVE YEARS
Indicate by check mark whether the registrant has filed all documents
and reports required to be filed by Section 12, 13 or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan
confirmed by a court. YES [ ]. NO [ ].
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date.
18,660,604 shares of Common Stock
as of November 30, 1995
Page 1 of 14 pages
<PAGE> 2
PART I -- FINANCIAL INFORMATION
ITEM 1 FINANCIAL STATEMENTS
The following financial statements required to be provided by this Item
1 and Rule 10.01 of Regulation S-X are filed herewith, at the respective pages
indicated on this Quarterly Report, Form 10-Q:
<TABLE>
<CAPTION>
Page
----
<S> <C>
Balance Sheets at April 30, 1995 and October 31, 1995 (unaudited) . . . . . . . . . . . 7, 8
Statements of Operations for the periods from August 1, 1994
to October 31, 1994 and from August 1, 1995 to October 31, 1995;
from May 1, 1994 to October 31, 1994 and from May 1, 1995 to
October 31, 1995 (unaudited) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Statement of Stockholders' Deficit for the period from April 30, 1995
through October 31, 1995 (unaudited) . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Statements of Cash Flows for the periods August 1, 1994 to October 31, 1994
and from August 1, 1995 to October 31, 1995; from May 1, 1994 to
October 31, 1994 and from May 1, 1995 to October 31, 1995 (unaudited) . . . . . . . . . 11, 12
Notes to Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
</TABLE>
ITEM 2 -- MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
RESULTS OF OPERATIONS
The Company's net loss of $539,021 for the quarter ended October 31,
1995 increased $189,578 in comparison to the net loss of $349,443 for the prior
year quarter ended October 31, 1994. This increased quarterly loss is
primarily attributable to a $56,193 increase in general and administrative
expenses and a $133,175 increase in research and development expenses during
the quarter ended October 31, 1995 in comparison to the prior year quarter
ended October 31, 1994. The Company's net loss of $1,054,123 for the six
months ended October 31, 1995 represents a decrease of $4,514,830 in comparison
to the net loss of $5,568,953 for the six months ended October 31, 1994. This
decrease in year-to-date loss is primarily attributable to a decrease in current
year quarterly total costs and expenses including an aggregate charge to
earnings of $4,835,140 which occurred during the six months ended October 31,
1994 (which represented the excess of the fair market value of the Company
stock issued over the net assets acquired of CBI, plus an additional
non-recurring charge relating to CBI stock options assumed by the Company) in
connection with the merger of Cancer Biologies Incorporated ("CBI") with and
into the Company, and which did not recur during the current year, and a
decrease in interest expense of $1,762, partially offset by a $124,901 increase
in general and administrative expenses and a $193,479 increase in research and
development expenses during the six months ended October 31, 1995.
Revenues for the quarter ended October 31, 1995 decreased $1,033
compared to the same prior year period ended October 31, 1994. This decrease
resulted from a $1,033 decrease in interest income during the quarter ended
October 31, 1995 in comparison to the same prior year period ended October 31,
1994.
2
<PAGE> 3
Revenues for the six months ended October 31, 1995 decreased $3,692 compared
to the same prior year period ended October 31, 1994. Licensing fees decreased
$2,633 during the six months ended October 31, 1995 in comparison to the same
prior year period ended October 31, 1994 due to decreased in current year
licensing fees relating to the Company's Histoclone diagnostic antibodies.
Management expects revenues from the sales and licensing of antibodies to
increase during the remainder of the fiscal year ending April 30, 1996 as the
Company commences Phase III clinical trials for the LYM-1 antibody. Interest
and other income has decreased during the current year as the level of idle
cash funds available for investment has decreased in comparison to the prior
year quarter ended October 31, 1994.
The Company's total costs and expenses increased $188,545 during the
quarter ended October 31, 1995, in comparison to the same prior year period
ended October 31, 1994. This increase resulted primarily from a $133,175
increase in research and development expenses and a $56,193 increase in general
and administrative expenses in comparison to the prior year quarter ended
October 31, 1994. The Company's total costs and expenses decreased $4,518,522
for the six months ended October 31, 1995 in comparison to the same prior year
period ended October 31, 1994. This decrease in total costs and expenses is
primarily attributable to the aggregate charge to earnings of $4,835,140
incurred during the prior year relating to the merger of CBI which did not
recur during the current year. Research and development expenses increased
$133,175 for the quarter and $193,479 for the six months ended October 31, 1995
in comparison to the same prior year periods. The increase in research and
development costs resulted from the Company's activities during the current
year in preparing for Phase III clinical trials of the LYM-1 antibody.
General and administrative expenses increased $56,193 for the quarter
and $124,901 for the six months ended October 31, 1995 in comparison to the
same periods of the prior year. This increase in current year expenses has
resulted primarily from increased administrative, payroll and consultant costs
associated with clinical trial preparation. Interest expense decreased $823
during the quarter and $1,762 for the six months ended October 31, 1995 in
comparison to the same periods of the prior year due to a slightly lower level
of interest bearing debt outstanding during the current year. The Company
believes that general and administrative costs will increase during the
remainder of the current fiscal year as Phase III clinical trials of the LYM-1
antibody commence.
LIQUIDITY AND CAPITAL RESOURCES
At October 31, 1995, the Company had $349,346 in cash and receivables
and a working capital deficit of $579,333 compared to $38,020 in cash and
receivables and a working capital deficit of $934,121 at April 30, 1995. The
Company raised $1,020,802 from the sale of Common Stock and exercise of stock
options during the quarter ended October 31, 1995 and raised $1,318,952 from
Common Stock sales and stock option exercises during the six months ended
October 31, 1995.
The Company's auditor's report on its financial statements for the
year ended April 30, 1995 indicates that its recurring losses, accumulated
deficit and working capital deficit raise substantial doubt about its ability
to continue as a going concern. The Company does not have sufficient cash to
sustain operations for the next twelve months without obtaining additional
capital. Accordingly, the Company will have to raise additional capital to
fund continued development of its antibodies and the Phase III clinical trials
of LYM-1 and to continue operations. The Company believes that it may be able
to raise additional capital through the sale of additional equity securities,
however no assurance can be given that the Company can raise additional capital
or that any additional capital raised would be sufficient to fund the
development of LYM-1 and the Phase III clinical trials and to continue
operations. If the Company is not successful in its efforts to raise
additional capital, then it will have to reduce its expenditures and may not be
able to proceed with Phase III clinical trials. The failure to obtain needed
financing could have a material adverse effect on business and financial
condition of the Company.
3
<PAGE> 4
CAPITAL COMMITMENTS
During the year ending April 30, 1996, the Company expects to acquire
additional assets, however, at October 31, 1995, the Company had no material
commitments for capital expenditures.
FACTORS THAT MAY AFFECT FUTURE RESULTS
At October 31, 1995 the Company had $349,346 in cash which
approximates two months of expenses. The Company has continued to experience
negative cash flows since October 31, 1995 and expects the negative cash flow
to continue for the foreseeable future. To continue operating and to proceed
with Phase II/III clinical trials for LYM-1, the Company cannot significantly
reduce its operating expenses. The Company has very few tangible assets upon
which it can borrow money. Therefore the Company must raise additional equity
funds in order to continue its operations and there can be no assurance that
the Company will be successful in acquiring such funds on terms acceptable to
it or at all or that any additional capital raised would be sufficient to fund
the development of LYM-1 or the Company's continued operations.
If the Company is unable to obtain sufficient financing to proceed
with its Phase II/III clinical trials for LYM-1 or if the initial results from
the Phase II/III clinical trials are poor, the Company may not be able to raise
additional financing which would have a material adverse effect on the
Company's financial condition and on its ability to continue its operations.
The Company has developed strategic relationships with Alpha
Therapeutic Corporation and other entities and persons. The Company's
dependence on these relationships raises certain risks with respect to the
future success of the Company and its business.
The bio-tech industry is intensely competitive and changing rapidly.
Substantially all of the Company's existing competitors have larger technical
staff, more established and larger research budgets and significantly greater
financial resources than the Company. There can be no assurance that these
competitors will not be able to expend resources to develop their products
prior to the Company's product being granted approval for marketing by the U.S.
Food and Drug Administration. There can be no assurance that the Company will
be able to compete successfully or that competition will not have a material
adverse effect on the Company's results of operation.
The Company's future success will depend significantly upon its
ability to develop and test workable products which the Company will seek FDA
approval to market to certain defined groups. A significant risk remains as to
the technological, performance and commercial success of the Company's
technology and products.
The Company's products are subject to extensive government regulation
in the United States by federal, state and local agencies including the Food
and Drug Administration. The process of obtaining and maintaining FDA and
other required regulatory approvals for the Company's products is lengthy,
expensive and uncertain. There can be no assurance that the Company can obtain
FDA or other regulatory approval for the marketing of its products or that
changes in existing regulations or the adoption of new regulations will not
occur which will adversely affect the Company.
Because of these and other factors affecting the Company's operating
results, including the uncertainties relating to the raising of additional
capital, the results of the Phase II/III clinical trials, the Company's
reliance on strategic relationships, competition and government regulation
investors should carefully consider whether any of the above events might
affect future results or the Company's ability to raise additional capital.
4
<PAGE> 5
PART II
Item 1. Legal Proceedings. None.
Item 2. Changes in Securities. None.
Item 3. Defaults Upon Senior Securities. None.
Item 4. Submission of Matters to a Vote of Security Holders. None.
Item 5. Other Information. None.
Item 6. Exhibits and Report on Form 8-K.
(a) Exhibits:
27 Financial Data Schedules (filed herewith)
(b) Reports on Form 8-K: None.
5
<PAGE> 6
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
TECHNICLONE INTERNATIONAL CORPORATION
By: /ss/ Lon H. Stone
---------------------------------
By: /ss/ William V. Moding
---------------------------------
6
<PAGE> 7
TECHNICLONE INTERNATIONAL CORPORATION
BALANCE SHEETS
<TABLE>
<CAPTION>
April 30, October 31,
1995 1995
---------- ----------
(Unaudited)
<S> <C> <C>
ASSETS
CURRENT ASSETS:
Cash . . . . . . . . . . . . . . . . . . . . . . . . $ 35,642 $ 349,346
Receivables . . . . . . . . . . . . . . . . . . . . . 2,378 --
Inventories . . . . . . . . . . . . . . . . . . . . . 226,457 245,000
----------- -------------
Total current assets . . . . . . . . . . . . . . . . 264,477 594,346
----------- -------------
PROPERTY:
Laboratory equipment . . . . . . . . . . . . . . . . 985,026 1,002,610
Furniture and fixtures . . . . . . . . . . . . . . . 30,844 32,100
----------- -------------
Total . . . . . . . . . . . . . . . . . . . . . . . . 1,015,870 1,034,710
Less accumulated depreciation
and amortization . . . . . . . . . . . . . . . . . (583,328) (648,691)
----------- -------------
Property--net . . . . . . . . . . . . . . . . . . . . 432,542 386,019
----------- -------------
OTHER ASSETS
Patents--net . . . . . . . . . . . . . . . . . . . . 154,081 167,745
Other . . . . . . . . . . . . . . . . . . . . . . . . 5,557 5,557
----------- -------------
Total other assets . . . . . . . . . . . . . . . . . 159,638 173,302
----------- -------------
TOTAL . . . . . . . . . . . . . . . . . . . . . . . . $ 856,657 $ 1,153,667
=========== =============
</TABLE>
See accompanying notes to financial statements.
7
<PAGE> 8
TECHNICLONE INTERNATIONAL CORPORATION
BALANCE SHEETS
<TABLE>
<CAPTION>
April 30, October 31,
1995 1995
---------- -----------
(Unaudited)
<S> <C> <C>
LIABILITIES AND STOCKHOLDERS'
- -----------------------------
DEFICIT
- -------
CURRENT LIABILITIES:
Accounts payable . . . . . . . . . . . . . . . . . . $ 137,878 $ 103,722
Accrued legal and accounting fees
(primarily to a related party) . . . . . . . . . . 334,741 318,024
Accrued payroll and related costs . . . . . . . . . . 260,301 220,391
Accrued license termination fee . . . . . . . . . . . 100,000 100,000
Accrued royalties . . . . . . . . . . . . . . . . . . 75,168 95,168
Accrued interest . . . . . . . . . . . . . . . . . . 90,910 101,250
Reserve for contract losses . . . . . . . . . . . . . 132,071 132,071
Other current liabilities . . . . . . . . . . . . . . 67,529 103,053
------------ -------------
Total current liabilities . . . . . . . . . . . . . . 1,198,598 1,173,679
------------ -------------
LONG TERM DEBT TO RELATED PARTY . . . . . . . . . . . 258,500 258,500
------------ -------------
COMMITMENTS
STOCKHOLDERS' DEFICIT:
Preferred Stock--$1.00 par value (authorized,
100,000 shares; Class A Convertible Preferred
Stock, outstanding, 4,225 shares at April 30, 1995
and at October 31, 1995)
(liquidation preference of $253,500) . . . . . . . 4,225 4,225
Common Stock--no par value (authorized,
30,000,000 shares; outstanding, 16,768,909
shares at April 30, 1995 and 18,643,374
shares at October 31, 1995) . . . . . . . . . . . . 17,730,648 19,106,700
Paid-in capital . . . . . . . . . . . . . . . . . . 227,246 227,246
Accumulated deficit . . . . . . . . . . . . . . . . . (18,085,978) (19,140,101)
----------- ----------
Total . . . . . . . . . . . . . . . . . . . . . . . . (123,859) 198,070
Less notes receivable from sale of common stock . . . (476,582) (476,582)
------------ -------------
Net stockholders' deficit . . . . . . . . . . . . . . (600,441) (278,512)
------------ -------------
TOTAL . . . . . . . . . . . . . . . . . . . . . . . . $ 856,657 $ 1,153,667
============ =============
</TABLE>
See accompanying notes to financial statements.
8
<PAGE> 9
TECHNICLONE INTERNATIONAL CORPORATION
STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
THREE MONTHS ENDED SIX MONTHS ENDED
OCTOBER 31, OCTOBER 31, OCTOBER 31, OCTOBER 31,
1994 1995 1994 1995
-------------- -------------- ------------ --------------
(Unaudited) (Unaudited) (Unaudited) (Unaudited)
<S> <C> <C> <C> <C>
REVENUES:
Net sales . . . . . . . . . . . . . $ -- $ -- $ -- $ --
Licensing fees . . . . . . . . . . -- -- 2,633 --
Interest and other income . . . . . 1,043 10 1,080 21
------------ -------------- -------------- ---------------
Total revenues . . . . . . . . . . 1,043 10 3,713 21
------------ -------------- -------------- ---------------
COSTS AND EXPENSES:
Cost of sales . . . . . . . . . . . -- -- -- --
Research and development . . . . . 203,597 336,772 407,349 600,828
General and administrative:
Unrelated entities . . . . . . 109,607 161,137 244,937 374,489
Affiliates . . . . . . . . . . 30,262 34,925 70,863 66,212
Interest . . . . . . . . . . . . . 7,020 6,197 14,377 12,615
Cost in excess of net assets
acquired of subsidiary . . . . -- -- 4,835,140 --
------------ -------------- -------------- ---------------
Total costs and expenses . . . . . 350,486 539,031 5,572,666 1,054,144
------------ -------------- -------------- ---------------
NET LOSS . . . . . . . . . . . . . $ (349,443) $ (539,021) $ (5,568,953) $ (1,054,123)
------------ -------------- -------------- ---------------
WEIGHTED AVERAGE SHARES
OUTSTANDING . . . . . . . . . . . 15,944,205 18,070,954 15,720,224 17,503,998
============ ============== ============== ===============
LOSS PER COMMON SHARE . . . . . . . $ (.02) $ (.03) $ (.35) $ (.06)
============ ============== ============== ===============
</TABLE>
See accompanying notes to financial statements.
9
<PAGE> 10
TECHNICLONE INTERNATIONAL CORPORATION
STATEMENT OF STOCKHOLDERS' DEFICIT
<TABLE>
<CAPTION>
NOTES
RECEIVABLE
PREFERRED STOCK COMMON STOCK ACCUMU- FROM
--------------- --------------------- PAID-IN LATED SALE OF
SHARES AMOUNT SHARES AMOUNT CAPITAL DEFICIT STOCK TOTAL
------ ------ ------ ------- ------- ----------- ------------ -----------
<S> <C>
BALANCE AT
- ----------
APRIL 30, 1995 . . . . . 4,225 $4,225 16,768,909 $17,730,648 $ 227,246 $(18,085,978) $(476,582) $ (600,441)
Common stock issued
for cash (unaudited) . . 1,758,165 1,289,352 1,289,352
Common stock issued
in exchange for
services (unaudited) . . 57,100 57,100 57,100
Common stock issued
upon exercise of
options (unaudited) . . 59,200 29,600 29,600
Net loss
(unaudited) . . . . . . (1,054,123) (1,054,123)
BALANCE AT
- ----------
OCTOBER 31,1995 . . . .
- --------------- ----- ------ ---------- ----------- ---------- ------------ ---------- -----------
(unaudited) . . . . . . 4,225 $4,225 18,643,374 $19,106,700 $ 227,246 $(19,140,101) $ (476,582) $ (278,512)
===== ====== ========== =========== ========== ============ ========== ===========
</TABLE>
See accompanying notes to financial statements.
10
<PAGE> 11
TECHNICLONE INTERNATIONAL CORPORATION
STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
THREE MONTHS ENDED SIX MONTHS ENDED
OCTOBER 31, OCTOBER 31, OCTOBER 31, OCTOBER 31,
1994 1995 1994 1995
-------------- -------------- ------------ --------------
(Unaudited) (Unaudited) (Unaudited) (Unaudited)
<S> <C> <C> <C> <C>
CASH FLOWS FROM
OPERATING ACTIVITIES:
Net loss . . . . . . . . . . . . . $ (349,443) $ (539,021) $ (5,568,953) $ (1,054,123)
Adjustments to reconcile net
income to net cash provided
by operating activities:
Depreciation and amortization 37,568 40,404 74,909 87,918
Common stock issued
for services . . . . . . . -- -- -- 57,100
Cost in excess of net assets
acquired of subsidiary . . . . -- -- 4,835,140 --
Changes in operating assets and
liabilities:
Decrease in accounts receivables . -- -- -- 2,378
Increase in inventory . . . . . . . (115,365) (16,068) (233,685) (18,543)
Decrease in other assets . . . . . 900 -- 900 --
Increase in deposits . . . . . . . (14,400) -- (28,800) --
Increase (Decrease) in accounts
payable . . . . . . . . . . . . 31,791 (116,671) 76,509 (34,156)
Increase (Decrease) in accrued and
other current liabilities . . . 11,261 (86,532) 56,850 9,237
------------ -------------- -------------- ---------------
Net cash used by operating
activities . . . . . . . . . . . (397,688) (717,888) (787,130) (950,189)
------------ -------------- -------------- ---------------
CASH FLOWS FROM INVESTING
ACTIVITIES:
Property acquisitions . . . . . . . -- (7,906) (3,461) (26,340)
Patent costs capitalized . . . . . (9,051) 6,556 (9,869) (28,719)
------------ -------------- -------------- ---------------
Net cash used by investing
activities . . . . . . . . . . . (9,051) (1,350) (13,330) (55,059)
------------ -------------- -------------- ---------------
</TABLE>
[Continued on next page]
See accompanying notes to financial statements.
11
<PAGE> 12
TECHNICLONE INTERNATIONAL CORPORATION
STATEMENTS OF CASH FLOWS
[Continued from previous page]
<TABLE>
<CAPTION>
THREE MONTHS ENDED SIX MONTHS ENDED
OCTOBER 31, OCTOBER 31, OCTOBER 31, OCTOBER 31,
1994 1995 1994 1995
---------- ---------- ---------- ----------
(Unaudited) (Unaudited) (Unaudited) (Unaudited)
<S> <C> <C> <C> <C>
CASH FLOWS FROM FINANCING
ACTIVITIES:
Principal payments on short-
and long-term borrowings . . . $ (3,926) $ -- $ (7,669) $ --
Proceeds from sale of common
stock . . . . . . . . . . . . 440,000 1,020,802 851,250 1,318,952
------------- ------------ ------------- ------------
Net cash provided by financing
activities . . . . . . . . . . . 436,074 1,020,802 843,581 1,318,952
------------- ------------ ------------- ------------
INCREASE IN CASH . . . . . . . . 29,335 301,564 43,121 313,704
CASH AT BEGINNING
OF PERIOD . . . . . . . . . . . 42,888 47,782 29,102 35,642
------------- ------------ ------------- ------------
CASH AT END OF PERIOD . . . . . . $ 72,223 $ 349,346 $ 72,223 $ 349,346
============= ============ ============= ============
SUPPLEMENTAL INFORMATION:
Costs in excess of net assets acquired
of subsidiary:
Common stock issued . . . . $ -- $ -- $ 2,504,053 $ --
Stock options assumed . . . -- -- 2,577,120 --
Notes receivable acquired . -- -- (231,582) --
Minority interest eliminated $ -- $ -- $ (14,451) $ --
------------- ------------ ------------- ------------
$ -- $ -- $ 4,835,140 $ --
============= ============ ============= ============
Interest paid . . . . . . . . . . . $ 1,850 $ 1,027 $ 4,037 $ 2,275
============= ============ ============= ============
Income taxes paid . . . . . . . . . $ -- $ -- $ 1,600 $ 800
============= ============ ============= ============
</TABLE>
See accompanying notes to financial statements.
12
<PAGE> 13
TECHNICLONE INTERNATIONAL CORPORATION
NOTES TO FINANCIAL STATEMENTS
(1) The accompanying unaudited financial statements contain all
adjustments (consisting of only normal recurring adjustments) which,
in the opinion of management, are necessary to present fairly the
financial position of the Company at October 31, 1995, and the results
of its operations and its cash flows for the three and six month
periods ended October 31, 1995 and 1994. Certain information and
footnote disclosures normally included in the financial statements
have been condensed or omitted pursuant to rules and regulations of
the Securities and Exchange Commission although the Company believes
that the disclosures in the financial statements are adequate to make
the information presented not misleading. The financial statements
included herein should be read in conjunction with the financial
statements of the Company, included in the Company's Annual Report on
Form 10-K for the year ended April 30, 1995, filed with the Securities
and Exchange Commission on July 29, 1995.
(2) Going Concern -- The accompanying financial statements have been
prepared on a going concern basis, which contemplates the realization
of assets and the satisfaction of liabilities in the normal course of
business. As shown in the financial statements, the Company has
suffered recurring losses, has a working capital deficit and an
accumulated deficit at October 31, 1995. Management has restructured
certain of its license agreements to provide it with greater control
over the development and clinical trials of its antibodies.
Additional financing is contingent upon achieving certain goals
pursuant to terms of an existing licensing agreement. Clinical trial
testing of the Company's antibodies is required before submission for
FDA approval can be made. If clinical trial test results are poor,
then the Company may not be able to raise additional funding which
would have a material adverse effect on the Company. There can be no
assurance that the FDA will approve the Company's antibodies and if
approval is not granted, then it would have a material adverse effect
on the Company. Recently, the Company has relied on third party and
investor funds to fund its operations and clinical trials and
management expects to receive additional funds from these sources in
the future. However, there can be no assurances that this funding
will continue and the Company may need to seek alternative sources for
financing. If the Company does not receive additional funding, it
will be forced to scale back operations and may not be able to proceed
with the clinical trials of its antibodies which could have a material
adverse effect on the Company. The Company's continuation as a going
concern is dependent on its ability to generate sufficient cash flow,
to meet its obligations on a timely basis, to obtain additional
financing as may be required and, ultimately to attain successful
operations. However, no assurance can be given at this time as to
whether the Company will achieve the above. These factors, among
others, raise substantial doubt about the Company's ability to
continue as a going concern. The financial statements do not include
any adjustments relating to the recoverability and classification of
recorded asset amounts or the amounts and classification of
liabilities that might be necessary should the Company be unable to
continue as a going concern.
(3) Results of operations for the interim periods covered by this Report
may not necessarily be indicative of results of operations for the
full fiscal year.
13
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM FORM 10-K
FOR THE PERIOD ENDED 4/30/95 AND FORM 10-Q FOR THE PERIOD ENDED 10/31/95.
</LEGEND>
<CIK> 0000704562
<NAME> TECHNICLONE INTERNATIONAL CORPORATION
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> APR-30-1995
<PERIOD-START> MAY-01-1995
<PERIOD-END> OCT-31-1995
<EXCHANGE-RATE> 1,000
<CASH> 349
<SECURITIES> 0
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 245
<CURRENT-ASSETS> 594
<PP&E> 1,035
<DEPRECIATION> (649)
<TOTAL-ASSETS> 1,154
<CURRENT-LIABILITIES> 1,174
<BONDS> 0
<COMMON> 19,107
0
4
<OTHER-SE> (19,389)
<TOTAL-LIABILITY-AND-EQUITY> 1,154
<SALES> 0
<TOTAL-REVENUES> 0
<CGS> 0
<TOTAL-COSTS> 1,054
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 13
<INCOME-PRETAX> (1,054)
<INCOME-TAX> 0
<INCOME-CONTINUING> (1,054)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (1,054)
<EPS-PRIMARY> (.06)
<EPS-DILUTED> (.06)
</TABLE>
